Uma N. Sundram, MD, PhD

Publication Details

  • Immunophenotypic Analysis of Myeloperoxidase-Negative Leukemia Cutis and Blastic Plasmacytoid Dendritic Cell Neoplasm AMERICAN JOURNAL OF CLINICAL PATHOLOGY Cronin, D. M., George, T. I., Reichard, K. K., Sundram, U. N. 2012; 137 (3): 367-376


    Myeloid leukemia cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid LC (23 cases) from BPDCN (12 cases): myeloperoxidase, which stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN; CD56, which stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; CD4, which stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; CD123, which stained 4 cases (17%) of LC and 10 cases (83%) of BPDCN; and Tcl-1, which stained 2 cases (9%) of LC and 9 (82%) of 11 cases of BPDCN. It is interesting that CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. Our results indicate that a panel that includes CD4, CD56, CD123, and Tcl-1 can appropriately distinguish between these 2 entities.

    View details for DOI 10.1309/AJCP9IS9KFSVWKGH

    View details for Web of Science ID 000301081000005

    View details for PubMedID 22338048

Stanford Medicine Resources:

Footer Links: